

1 **Decreased cerebral blood flow in non-hospitalized adults who self-isolated due to COVID-**
2 **19**

3 **Running Title:** Cerebral blood flow and COVID-19

4 William S.H. Kim^{1,2}; Xiang Ji³; Eugenie Roudaia⁴; J. Jean Chen^{1,4,5}; Asaf Gilboa^{4,6}; Allison
5 Sekuler^{4,6,7}; Fuqiang Gao^{2,3}; Zhongmin Lin^{1,8}; Aravinthan Jegatheesan^{1,8}; Mario Masellis^{2,3,9};
6 Maged Goubran^{1,2,8,10}; Jennifer S. Rabin⁹⁻¹¹; Benjamin Lam^{2,3,9}; Ivy Cheng¹²⁻¹⁴; Robert
7 Fowler^{14,15}; Chris Heyn^{2,16}; Sandra E. Black^{2,3,9}; Simon J. Graham^{1,2,8,*}; Bradley J.
8 MacIntosh^{1,2,8,17,*}

9 ¹Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

10 ²Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada

11 ³LC Campbell Cognitive Neurology Research Group, Sunnybrook Health Sciences Centre,
12 Toronto, Ontario, Canada

13 ⁴Rotman Research Institute, Baycrest Academy for Research and Education, Toronto, Ontario,
14 Canada

15 ⁵Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada

16 ⁶Department of Psychology, University of Toronto, Toronto, Ontario, Canada

17 ⁷Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton,
18 Ontario, Canada

19 ⁸Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada

20 ⁹Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre,
21 University of Toronto, Toronto, Ontario, Canada

22 ¹⁰Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, Ontario,
23 Canada

24 ¹¹Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada

25 ¹²Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada

26 ¹³Integrated Community Program, Sunnybrook Research Institute, Toronto, Ontario, Canada

27 ¹⁴Department of Medicine, University of Toronto, Toronto, Ontario, Canada

28 ¹⁵Emergency & Critical Care Research Program, Sunnybrook Research Institute, Toronto,
29 Ontario, Canada

30 ¹⁶Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada

31 ¹⁷Computational Radiology & Artificial Intelligence Unit, Division of Radiology and Nuclear
32 Medicine, Oslo University Hospital, Oslo, Norway

33 * indicates senior authorship

34 **Corresponding Author:**

35 Bradley J. MacIntosh, Sunnybrook Research Institute, University of Toronto, 2075 Bayview
36 Avenue, Room M6-180, M4N 3M5, Toronto, ON, Canada

37 Email: brad.macintosh@utoronto.ca

38 **Abstract**

39 The long-term consequences of coronavirus disease 2019 (COVID-19) on brain physiology and
40 function are not yet well understood. From the recently described NeuroCOVID-19 study, we
41 examined cerebral blood flow (CBF) in 50 participants recruited to one of two groups: 1) adults
42 who previously self-isolated at home due to COVID-19 ($n = 39$; 116.5 ± 62.2 days since positive
43 diagnosis), or 2) controls who experienced flu-like symptoms but had a negative COVID-19
44 diagnosis ($n = 11$). Participants underwent arterial spin labeling magnetic resonance imaging at 3
45 T to yield measures of CBF. Voxel-wise analyses of CBF were performed to assess for between-
46 group differences, after controlling for age and sex. Relative to controls, the COVID-19 group
47 exhibited decreased CBF in the thalamus, orbitofrontal cortex, and regions of the basal ganglia.
48 Within the COVID-19 group, CBF differences in occipital and parietal regions were observed
49 between those with ($n = 11$) and without ($n = 28$) self-reported on-going fatigue. These results
50 suggest long-term changes in brain physiology in adults across the post-COVID-19 timeframe.
51 Moreover, CBF may aid in understanding the heterogeneous symptoms of the post-COVID-19
52 condition. Future longitudinal studies are needed to further characterize the consequences of
53 COVID-19 on the brain.

54 **Keywords:** cerebral blood flow; COVID-19; SARS-CoV-2; fatigue; post-COVID-19

55 1. Introduction

56 Growing evidence suggests that the consequences of severe acute respiratory syndrome
57 coronavirus 2 (SARS-CoV-2) infection extend beyond the respiratory system.^{1,2} As many as two
58 thirds of individuals suffering from coronavirus disease 2019 (COVID-19) are reported to
59 experience neurological and/or psychiatric symptoms during acute stages of infection.³⁻⁵ In some
60 cases, symptoms have been reported to persist or even develop in the months following
61 infection;⁶ this stage of COVID-19 has been referred to as the “post-COVID-19 condition” by
62 the World Health Organization. Symptoms such as fatigue and so-called “brain fog” prevail in
63 the post-COVID-19 timeframe;^{2,7,8} however, the long-term impact of COVID-19 on the brain is
64 not well characterized. Efforts aimed at describing the post-COVID-19 condition as it relates to
65 the brain are needed to mitigate pressure on strained healthcare systems worldwide.⁹

66 The effects of SARS-CoV-2 infection on the central nervous system are complex and
67 likely involve multiple potential pathways. One theorized pathway is the nasal mucosal route of
68 entry, whereby the virus may travel from the olfactory bulb to the primary olfactory cortex,
69 which has direct connections to several brain regions including the thalamus, orbitofrontal cortex,
70 and other midbrain regions;¹⁰ however, conclusive evidence of this pathway remains elusive.
71 Another potential pathway may involve SARS-CoV-2 infiltrating cells expressing the
72 angiotensin-converting enzyme (ACE-2) receptor, notably endothelial cells of the vasculature,¹¹
73 and thus constituents of the neurovascular unit. For example, stroke and cerebrovascular disease
74 secondary to COVID-19 have been reported.^{12,13} This notion of neurovascular involvement is
75 further supported by a recent study demonstrating SARS-CoV-2 infection of tissue-cultured
76 pericyte-like cells.¹⁴ In both cases, particularly the ACE-2 receptor pathway,¹⁵ SARS-CoV-2-
77 induced neuroinflammation is likely to contribute to the post-COVID-19 condition.

78 Neuroimaging studies have shown that COVID-19 is associated with alterations to brain
79 structure and/or punctate lesions (i.e., microbleeds, white matter hyperintensities), often in small
80 samples of acutely infected individuals.^{12,16–20} In a unique study using pre- and post-infection
81 data from a large UK Biobank sample, Douaud et al. observed longitudinal decreases in grey
82 matter thickness, particularly in limbic regions, among adults who self-isolated or were
83 hospitalized due to COVID-19.²¹ There are few cohort neuroimaging studies focusing on brain
84 physiology in the post-COVID-19 timeframe;^{1,22–28} such imaging contrasts may be particularly
85 relevant given the putative involvement of the vasculature in SARS-CoV-2 infection.^{29,30} Of the
86 studies that exist, most involve adults who were hospitalized or in intensive care due to a more
87 severe course of COVID-19.

88 As part of the Toronto-based NeuroCOVID-19 study,³¹ we conducted arterial spin
89 labeling (ASL) magnetic resonance imaging (MRI) to probe cerebral blood flow (CBF), a
90 measure of brain physiology and function, in non-hospitalized adults recovering from COVID-19.
91 Our primary aim was to compare voxel-wise CBF (with and without partial volume correction)
92 between adults who previously self-isolated at home due to COVID-19 and controls who
93 experienced flu-like symptoms but tested negative for COVID-19. We hypothesized that the
94 adults who previously self-isolated due to COVID-19 would exhibit altered CBF relative to
95 controls, when assessed weeks/months beyond infection. Given the prevalence of fatigue as a
96 symptom of the post-COVID-19 condition,^{7,8,32–35} we then performed an exploratory analysis of
97 the association between self-reported fatigue and CBF among COVID-19 participants.

98 **2. Materials and methods**

99 **2.1. Participants**

100 Participants in the current study were recruited between May 2020 and September 2021 through
101 the Department of Emergency Medicine at Sunnybrook Health Sciences Centre, physician
102 referral, and community advertisements. Eligibility and consenting procedures were performed
103 over phone or email. The Research Ethics Board at Sunnybrook Health Sciences Centre
104 approved this study.

105 Inclusion criteria for this study included being between 20 and 75 years of age and
106 having documented evidence of a positive or negative COVID-19 diagnosis, as determined by a
107 provincially-approved facility through a nasopharyngeal and/or oropharyngeal swab and
108 subsequent real-time reverse transcription polymerase chain reaction (PCR) test. Exclusion
109 criteria for this study included previous diagnosis of dementia, an existing neurological disorder,
110 previous traumatic brain injury, severe psychiatric illness, on-going unstable cardiovascular
111 disease, or contraindications to MRI (e.g., ferromagnetic implants).

112 **2.2. Study setting**

113 Sunnybrook Health Sciences Centre is an academic tertiary level hospital. Prior to the pandemic,
114 its emergency department received approximately 61,000 patients per year. Specialty services
115 include trauma, interventional cardiology, stroke, oncology, neurosurgery, psychiatry, and high-
116 risk obstetrics and gynecology. Its catchment area includes the Greater Toronto area and nearby
117 regions (<https://sunnybrook.ca/content/?page=care-programs>).

118 **2.3. Study design**

119 The current study is an observational cohort neuroimaging study and is part of the
120 NeuroCOVID-19 protocol, which has been previously described.³¹ We report on participants
121 who were recruited to one of two groups: 1) adults who previously self-isolated at home due to
122 COVID-19, or 2) controls who experienced flu-like symptoms but tested negative for COVID-19.
123 Herein, we refer to the former as the COVID-19 group and the latter as the control group. The
124 rationale for including this unique control group was that they may act as a better “baseline”
125 against which the COVID-19 group could be compared (i.e., a group with non-specific flu-like
126 symptoms who tested negative for COVID-19). Once non-infectious (i.e., following completion
127 of a 14-day quarantine period and/or a negative PCR test), participants were invited for an on-
128 site visit. Study staff and participants abided by the hospital’s infection prevention and control
129 guidelines.

130 The primary outcome measure of the current study is ASL-derived CBF. Other outcome
131 measures were assessed using: 1) a self-reported questionnaire of flu-like symptoms, 2) the
132 Cognition and Emotion Batteries from the National Institutes of Health (NIH) Toolbox,^{36,37} and 3)
133 the 40-odorant University of Pennsylvania Smell Identification Test (UPSIT, Sensonics
134 International).³⁸ The latter two assessments have been well-validated.^{39–41}

135 The self-reported questionnaire of symptoms assessed whether participants were
136 currently experiencing, had previously experienced, or had never experienced any flu-like
137 symptoms including: fever, cough, sore throat, shortness of breath, fatigue, gastrointestinal
138 symptoms, and/or smell/taste changes. Study staff ensured that symptoms were understood as
139 being impairing to activities of daily living.

140 The Cognition Battery from the NIH Toolbox resulted in two age-corrected standard
141 scores (mean = 100, standard deviation = 15) of fluid and crystallized cognition. The Emotion
142 Battery resulted in three T-scores (mean = 50, standard deviation = 10) of negative affect, social
143 satisfaction, and well-being. Note that a higher T-score for negative affect reflects more
144 unpleasant moods and/or emotions. The interpretation of these scores has been previously
145 described (<https://nihtoolbox.force.com/s/article/nih-toolbox-scoring-and-interpretation-guide>).

146 The UPSIT was administered as reports of olfactory dysfunction are a prevalent symptom
147 of COVID-19.^{7,8} This assessment resulted in an UPSIT score (calculated as the number of
148 odorants correctly identified) and a diagnosis of olfactory function (normosmia, mild hyposmia,
149 moderate hyposmia, severe hyposmia to total anosmia). These diagnoses were determined as a
150 function of UPSIT score and sex.

151 **2.4. MRI acquisition**

152 The MRI sequences used in this study consisted of T1-weighted and pseudo-continuous ASL
153 acquired on a 3 T MRI system (Magnetom Prisma, Siemens Healthineers, Erlangen, Germany).
154 T1-weighted images were acquired in three dimensions using an isotropic sagittal magnetization-
155 prepared rapid gradient-echo sequence (TR/TE/TI = 2500/4.7/1100 ms, spatial resolution = 1
156 mm³, field-of-view = 256 mm, slices = 192, duration = 3:45 min:s). ASL images were acquired
157 in three dimensions using an echo-planar turbo gradient-spin echo sequence with background
158 suppression (TR/TE = 4100/36.8 ms, isotropic spatial resolution = 2.5 mm³, field-of-view = 240
159 mm, label duration = 1500 ms, post-label delay = 1800 ms, 7 control-label pairs, duration = 4:27
160 min:s).⁴² Proton-density ASL reference images were acquired with a TR of 4.1 s for CBF
161 calibration.

162 **2.5. MRI processing**

163 MRI processing was performed using tools from the FMRIB Software Library (FSL, version
164 6.0.3).⁴³ T1-weighted images were processed using *fsl_anat* with steps that included brain
165 extraction, tissue segmentation, and non-linear registration to Montreal Neurological Institute
166 (MNI) space.

167 ASL images were processed using *oxford_asl* with steps that included motion correction,
168 spatial regularization,⁴⁴ generation of control-tag difference images, voxel-wise calibration using
169 the ASL reference image and assumed values from the literature,⁴⁵ linear registration to structural
170 space followed by non-linear registration to MNI space,⁴⁶ and spatial smoothing with a Gaussian
171 kernel of full-width at half maximum of 5 mm. The resulting CBF maps were then intensity-
172 normalized (i.e., each CBF map was scaled to a global mean of 1) to account for between-
173 participant global CBF differences.⁴⁷ Two individuals (WSHK, BJM) visually inspected the CBF
174 maps for quality control.

175 **2.6. Statistical analysis**

176 Demographic and clinical characteristics were compared between groups using independent
177 samples t-tests for continuous data and chi-squared tests for categorical data. In cases when
178 continuous data were non-normal (i.e., as assessed by the Shapiro-Wilk test), Mann-Whitney U-
179 tests were used. In cases when categorical data had an expected value less than 5 (i.e., in a
180 contingency table), Fisher's exact tests were used. The threshold for statistical significance of
181 demographic and clinical variables was set at 0.05.

182 For our primary aim, we performed between-group (i.e., COVID-19 vs. control) whole-
183 brain voxel-wise analyses of CBF using two-tailed independent samples t-tests, controlling for
184 age and sex. We used *3dFWHMx* and *3dClustSim* from the Analysis of Functional NeuroImages

185 (AFNI, version 22.0.05) to estimate cluster-extent thresholds at a family-wise error rate of 0.05
186 with a cluster-forming threshold of 0.005. In addition, we performed one sensitivity analysis and
187 one exploratory analysis in support of the primary aim.

188 *Sensitivity analysis – Partial volume correction:* We repeated the between-group
189 comparison (i.e., COVID-19 vs. control) after including partial volume correction as an
190 additional ASL processing step. The rationale for this sensitivity analysis is that ASL images
191 were collected at a spatial resolution similar to the average thickness of the cortex, which may
192 lead to biases in CBF estimation.⁴⁵ Thus, due diligence was required to interpret CBF estimates
193 and the resulting between-group differences. It is worth noting that currently available partial
194 volume correction methods are inconsistent and may hinder interpretation; thus, it is
195 recommended that partial volume correction be reported parallel to analyses using uncorrected
196 CBF estimates.⁴⁵ This additional processing step was implemented in *oxford_asl*.⁴⁸

197 *Exploratory analysis – Association between fatigue and CBF within the COVID-19 group:*
198 Given the prevalence of fatigue as a symptom of the post-COVID-19 condition,^{7,8,32,33} we
199 examined whether COVID-19 participants who self-reported as experiencing on-going fatigue (n
200 = 11) exhibited CBF differences compared to COVID-19 participants who previously reported
201 fatigue that had resolved by the time of the assessment or did not experience fatigue at all (n =
202 28). Fatigue was determined using the self-reported questionnaire of symptoms.

203 3. Results

204 3.1. Demographic & clinical characteristics

205 At the time of analysis, a total of 50 participants (39 COVID-19, 11 controls) met eligibility
206 criteria and had ASL and T1-weighted images available. Demographic and clinical
207 characteristics are presented in Table 1.

208 Briefly, groups were well-matched for age and sex. COVID-19 participants were scanned
209 116.5 ± 62.6 [8, 312] days after receiving a positive diagnosis. Self-reported fatigue (COVID-19,
210 28.2%; control, 36.4%) and shortness of breath (COVID-19, 20.5%; control, 27.3%) were the
211 most prevalent on-going symptoms across the cohort (Figure 1). Notably, 92.3% of COVID-19
212 participants and 72.7% of controls had experienced fatigue at some point between the PCR test
213 and the time of the assessment. Significantly more COVID-19 participants had previously
214 experienced or were currently experiencing smell/taste changes compared to controls ($X^2 = 6.04$,
215 $p < 0.05$). There were no between-group differences in fluid or crystallized cognition as assessed
216 by the NIH Toolbox Cognition Battery, negative affect, social satisfaction, or well-being as
217 assessed by the NIH Toolbox Emotion Battery (n.b., three COVID-19 participants did not
218 complete the Emotion Battery), or UPSIT score (n.b., 11 COVID-19 participants and two
219 controls had missing/faulty UPSIT data).

220 3.2. Differences in CBF between COVID-19 and control groups

221 Relative to controls, the COVID-19 group exhibited significantly decreased CBF in a large
222 cluster of voxels encompassing the thalamus, orbitofrontal cortex, and regions of the basal
223 ganglia, including the caudate, nucleus accumbens, putamen, and pallidum (Figure 2 and Table

224 2). There were no clusters in which the COVID-19 group had significantly increased CBF
225 relative to controls.

226 **3.3. Sensitivity analysis – Differences in CBF between COVID-19 and control groups** 227 **with partial volume correction**

228 Our sensitivity analysis with partial volume correction resulted in a similar cluster of smaller
229 extent compared to the primary analysis (Figure 3 and Table 2). Again, there were no clusters in
230 which the COVID-19 group had significantly increased CBF relative to controls.

231 **3.4. Exploratory analysis – Association between fatigue and CBF within the COVID-19** 232 **group**

233 Within the COVID-19 group, we observed between-subgroup CBF differences between those
234 with and without on-going fatigue. On-going fatigue was characterized by a cluster of increased
235 CBF in superior occipital and parietal regions (superior lateral occipital cortex, angular gyrus,
236 superior parietal lobule, supramarginal gyrus) and a cluster of decreased CBF in inferior occipital
237 regions (lingual gyrus, occipital fusiform gyrus, intracalcarine cortex, precuneus cortex) (Figure
238 4 and Table 2).

239 **4. Discussion**

240 In this study, we investigated whether adults who previously self-isolated at home due to
241 COVID-19 would exhibit alterations in CBF when compared against controls who experienced
242 flu-like symptoms but tested negative for COVID-19. COVID-19 participants exhibited
243 significantly decreased CBF in the thalamus, orbitofrontal cortex, and regions of the basal
244 ganglia compared to controls. We further examined the effect of fatigue within the COVID-19
245 group, which revealed between-subgroup CBF differences in occipital and parietal regions.

246 These results provide support for long-term changes in brain physiology in adults across the
247 post-COVID-19 timeframe.

248 Although COVID-19 is primarily a respiratory illness, the cerebrovasculature is also
249 susceptible to damage as endothelial cells and pericytes are prone to viral invasion.^{14,29} The
250 brain's vasculature interfaces with the complex neurovascular unit, for instance, in the regulation
251 of CBF.⁴⁹ Furthermore, the location of potential brain involvement in relation to SARS-CoV-2 is
252 likely to vary regionally, with some evidence to suggest that relative to the rest of the brain,
253 ACE-2 receptor expression is highest in the thalamus, the paraventricular nuclei of the thalamus,
254 and more generally in regions proximal to the ventricles.⁵⁰ Notably, we found significantly
255 decreased CBF in the anterior thalamus, which contains the paraventricular nuclei of the
256 thalamus, a key region of the brain's anxiety network.⁵¹ Moreover, decreased thalamic glucose
257 metabolism, as measured by positron emission tomography (PET), has been observed at both
258 acute and chronic stages of recovery from COVID-19.^{26,27,52}

259 Decreased CBF was also detected in regions of the basal ganglia, including the caudate,
260 nucleus accumbens, putamen, and pallidum. In particular, the caudate has been reported in a
261 longitudinal PET study that observed decreased glucose metabolism in seven adults recovering
262 from COVID-19, up to 6 months post-infection.²⁷ Multivariate methods have also revealed that
263 glucose metabolism within the caudate is a distinguishing feature between COVID-19 patients
264 and controls.²⁴ We also observed decreased CBF within the orbitofrontal cortex, a region widely
265 reported as being associated with SARS-CoV-2 infection.^{12,21,53-56} Together with the thalamus
266 and regions of the basal ganglia, the orbitofrontal cortex is a key region of the cortico-basal
267 ganglia-thalamic loop, a circuit involved in complex behaviours including affect regulation and
268 reward-based decision-making,⁵⁷ as well as in relation to neurological and psychiatric

269 disorders.^{58,59} Moreover, the orbitofrontal cortex also plays an important role in olfaction and is
270 often referred to as the secondary olfactory cortex.⁶⁰ The results of the current study align with
271 previous PET studies that find decreased glucose metabolism within the orbitofrontal cortex, and
272 more generally within the frontal lobe. In an early case report of one healthy 27-year-old with
273 COVID-19 experiencing persistent anosmia, Karimi-Galougahi et al. reported decreased glucose
274 metabolism in the left orbitofrontal cortex.⁵⁵ Hosp et al. reported frontoparietal hypometabolism
275 in 10 out of 15 adults with subacute COVID-19.²⁴ Guedj et al. reported frontal hypometabolism
276 in 35 adults that were 3 weeks beyond infection, and that significant clusters were correlated
277 with higher occurrence of symptoms, such as anosmia.²⁶ Finally, Kas et al. reported a consistent
278 pattern of orbitofrontal, dorsolateral, and mesiofrontal hypometabolism in seven adults with
279 acute COVID-19-related encephalopathy, despite heterogenous symptomatology, and posited
280 that COVID-19 is related to frontal lobe impairment.²⁷ Notably, the results from the latter study
281 persisted until 6 months following infection. Altogether, the result of decreased CBF within the
282 orbitofrontal cortex, along with the thalamus and regions of the basal ganglia, may reflect
283 COVID-19-related disturbances to brain networks, olfactory function, and emotional/cognitive
284 concerns. Future studies extending these potentially brain network-related results through
285 investigations of functional and structural connectivity are warranted.

286 It is important to note that participants in the current study were recruited over the course
287 of several pandemic waves in Ontario, each being associated with a different distribution of
288 variants of concern (Figure 1). Thus, it is probable that COVID-19 participants were infected
289 with different strains of SARS-CoV-2, likely spanning from the Alpha variant to the Delta
290 variant. We further note that these participants were recruited prior to the emergence of the

291 Omicron variant which, despite its high transmissibility, is believed to be less severe than
292 previous strains.^{61,62}

293 Our comparison of COVID-19 participants with and without fatigue resulted in between-
294 subgroup CBF differences, primarily in occipital and parietal regions of the brain. There have
295 been efforts to characterize COVID-19 based on symptoms, with the hope of predicting severity
296 and likelihood of the post-COVID-19 condition.^{32,33} Others have observed fatigue-related
297 differences in brain structure and function in those recovering from COVID-19,³⁵ such as
298 functional connectivity alterations in parietal regions.³⁴ Interestingly, the post-COVID-19
299 condition shares many common features with chronic fatigue syndrome (i.e., myalgic
300 encephalomyelitis), a disorder that can be triggered by viral infection,⁶³ and that is characterized
301 by decreased CBF, such as within the lingual gyrus.^{64,65} Therefore, these fatigue-related CBF
302 differences amongst COVID-19 participants could help guide therapeutic efforts in treating
303 fatigue as a symptom of the post-COVID-19 condition. We note that while brain-behaviour
304 investigations in the context of COVID-19 are important in understanding symptoms, this
305 fatigue-related analysis is a “scratch of the surface”. Higher-order multivariate analyses (e.g.,
306 principal component analysis) with larger sample sizes will be better poised to answer such
307 questions.

308 These results need to be interpreted in the context of several limitations. First, although
309 well-matched, the sample sizes of the two groups were modest and unequal; furthermore, a
310 power analysis was not performed. To our knowledge, the current study benefits from the largest
311 ASL dataset focusing on non-hospitalized adults in the post-COVID-19 timeframe. Moreover,
312 recruitment for the NeuroCOVID-19 study is on-going and will address these issues in future
313 studies. Second, our recruitment may be confounded by selection bias. For example, the current

314 study's cohort was comprised of 66% female and 72% Caucasian participants. We further note
315 that participants needed internet access to be screened for eligibility. Third, our control group
316 exhibited flu-like symptoms of unknown origin. The recruitment of this unique control group is a
317 relatively novel aspect of this study, as these participants are a de-novo sample of adults that
318 experienced non-specific flu-like symptoms during the pandemic. Fourth, ASL images were
319 acquired at a spatial resolution comparable to the average thickness of the cortex, which may be
320 susceptible to partial volume error.⁴⁵ To address this, we included partial volume correction as an
321 additional ASL processing step in a sensitivity analysis, which did not drastically change the
322 results. Fifth, our fatigue-related exploratory analysis relied on self-reported symptoms. Study
323 staff ensured that on-going fatigue was understood as being impairing to activities of daily living.
324 Finally, the data used in this study are cross-sectional and lack a pre-infection assessment.²¹
325 Further investigation into longitudinal changes of these participants will be performed as part of
326 the NeuroCOVID-19 study. It may also be feasible to access pre-pandemic repository data from
327 age- and sex-matched individuals.

328 In conclusion, we observed decreased CBF in those recovering from COVID-19 relative
329 to controls. These decreases were present months after acute infection and were localized to
330 regions that have previously been highlighted as related to SARS-CoV-2 infection. We also
331 observed CBF differences in relation to fatigue within the COVID-19 group, suggesting that
332 CBF may aid in parsing the heterogeneous symptoms associated with the post-COVID-19
333 condition. In all, these results suggest that the post-COVID-19 condition may be associated with
334 long-term effects on brain physiology and function. Future studies that replicate and further
335 characterize such effects are warranted.

336 **Acknowledgments**

337 The authors wish to thank all study participants and staff (Ellen Cohen, Garry Detzler, Ruby
338 Endre, Haddas Grosbein, Masud Hussain, Devin Sodums) for their time and contributions to this
339 study. We thank Dr. Danny J.J. Wang from the University of Southern California for providing
340 the 3D pCASL sequence.

341 **Funding**

342 This study is funded in part by the Sunnybrook Foundation, the Dr. Sandra Black Centre for
343 Brain Resilience & Recovery, a Canadian Institutes of Health Research (CIHR) Project Grant
344 (165981), and a CIHR Operating Grant on Emerging COVID-19 Research Gaps and Priorities
345 (177756).

346 **Authors' contributions**

347 Study design: WSHK, XJ, ER, JJC, AG, AS, FG, ZL, AJ, MM, MG, JR, BL, IC, RF, CH, SEB,
348 SJG, BJM. Data collection: XJ, ER, ZL, AJ, SJG, BJM. Data analysis and interpretation: WSHK,
349 XJ, ER, JJC, AG, AS, FG, ZL, AJ, MM, MG, JR, BL, IC, RF, CH, SEB, SJG, BJM. Manuscript
350 writing: WSHK, XJ, ER, JJC, ZL, SJG, BJM. All authors revised and approved the final version
351 of this manuscript.

352 **Declaration of conflicting interests**

353 SEB reports payments for contract research to her institution from GE Healthcare, Eli Lilly and
354 Company, Biogen, Genentech, Optina Diagnostics, and Roche; consulting fees and payments
355 related to an advisory board from Roche; and payments related to an advisory board, a speaker
356 panel, talks, and an educational session from Biogen. There were peer-reviewed grants to her
357 institution from the Ontario Brain Institute, Canadian Institutes of Health Research, Leducq

358 Foundation, Heart and Stroke Foundation of Canada, National Institutes of Health, Alzheimer's
359 Drug Discovery Foundation, Brain Canada, Weston Brain Institute, Canadian Partnership for
360 Stroke Recovery, Canadian Foundation for Innovation, Focused Ultrasound Foundation,
361 Alzheimer's Association US, Department of National Defence, Montreal Medical International-
362 Kuwait, Queen's University, Compute Canada Resources for Research Groups, CANARIE, and
363 Networks of Centres of Excellence of Canada. She has participated on a data safety monitoring
364 board or advisory board for the Conference Board of Canada, World Dementia Council, and
365 University of Rochester. She has contributed to the mission and scientific leadership of the Small
366 Vessel VCID Biomarker Validation Consortium, National Institute of Neurological Disorders
367 and Stroke. No other conflicting interests were declared.

368 **5. References**

- 369 1. Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2
370 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental
371 health, post-hospital discharge. *EClinicalMedicine*. 2021;31.
372 doi:10.1016/j.eclinm.2020.100683
- 373 2. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*.
374 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
- 375 3. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric
376 complications of COVID-19 in 153 patients: a UK-wide surveillance study. *The Lancet*
377 *Psychiatry*. 2020;7(10):875-882. doi:10.1016/S2215-0366(20)30287-X
- 378 4. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients with
379 Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. Published online 2020.
380 doi:10.1001/jamaneurol.2020.1127
- 381 5. Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection.
382 *N Engl J Med*. 2020;382(23):2268-2270. doi:10.1056/nejmc2008597
- 383 6. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and
384 psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study
385 using electronic health records. *The Lancet Psychiatry*. 2021;8(5):416-427.
386 doi:10.1016/S2215-0366(21)00084-5
- 387 7. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of
388 COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2021;11(1):1-12.
389 doi:10.1038/s41598-021-95565-8
- 390 8. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat*

- 391 *Med.* 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- 392 9. Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome
393 and implications for healthcare service planning: A population-based cohort study. *PLoS*
394 *One.* 2021;16(7 July):e0254523. doi:10.1371/journal.pone.0254523
- 395 10. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion
396 as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci.*
397 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5
- 398 11. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J.*
399 2020;41(32):3038-3044. doi:10.1093/eurheartj/ehaa623
- 400 12. Manca R, De Marco M, Ince PG, Venneri A. Heterogeneity in Regional Damage Detected
401 by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A
402 Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus
403 on Neurocognitive Trajectories. *Front Aging Neurosci.* 2021;13:646908.
404 doi:10.3389/fnagi.2021.646908
- 405 13. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. *Lancet*
406 *Neurol.* 2020;19(9):767-783. doi:10.1016/S1474-4422(20)30221-0
- 407 14. Wang L, Sievert D, Clark AE, et al. A human three-dimensional neural-perivascular
408 ‘assembloid’ promotes astrocytic development and enables modeling of SARS-CoV-2
409 neuropathology. *Nat Med.* 2021;27(9):1600-1606. doi:10.1038/s41591-021-01443-1
- 410 15. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. *JAMA Psychiatry.*
411 2021;78(6):682-683. doi:10.1001/jamapsychiatry.2021.0500
- 412 16. Chougar L, Shor N, Weiss N, et al. Retrospective Observational Study of Brain Magnetic
413 Resonance Imaging Findings in Patients with Acute SARS-CoV-2 Infection and

- 414 Neurological Manifestations. *Radiology*. Published online 2020.
- 415 17. Kremer S, Lersy F, De Sèze J, et al. Brain MRI findings in severe COVID-19: A
416 retrospective observational study. *Radiology*. 2020;297(2):E242-E251.
417 doi:10.1148/RADIOL.2020202222
- 418 18. Kremer S, Lersy F, Anheim M, et al. Neurologic and neuroimaging findings in patients
419 with COVID-19: A retrospective multicenter study. *Neurology*. 2020;95(13):e1868-e1882.
420 doi:10.1212/WNL.00000000000010112
- 421 19. Gulko E, Oleksk ML, Gomes W, et al. MRI brain findings in 126 patients with COVID-19:
422 Initial observations from a descriptive literature review. *Am J Neuroradiol*.
423 2020;41(12):2199-2203. doi:10.3174/ajnr.A6805
- 424 20. Kandemirli SG, Dogan L, Sarikaya ZT, et al. Brain MRI findings in patients in the
425 intensive care unit with COVID-19 infection. *Radiology*. 2020;297(1):E232-E235.
426 doi:10.1148/radiol.2020201697
- 427 21. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in
428 brain structure in UK Biobank. *Nature*. Published online March 7, 2022:1-17.
429 doi:10.1038/s41586-022-04569-5
- 430 22. Griffanti L, Raman B, Alfaro-Almagro F, et al. Adapting the UK Biobank Brain Imaging
431 Protocol and Analysis Pipeline for the C-MORE Multi-Organ Study of COVID-19
432 Survivors. *Front Neurol*. 2021;12:753284. doi:10.3389/fneur.2021.753284
- 433 23. Qin Y, Wu J, Chen T, et al. Long-term microstructure and cerebral blood flow changes in
434 patients recovered from COVID-19 without neurological manifestations. *J Clin Invest*.
435 2021;131(8). doi:10.1172/JCI147329
- 436 24. Hosp JA, Dressing A, Blazhenets G, et al. Cognitive impairment and altered cerebral

- 437 glucose metabolism in the subacute stage of COVID-19. *Brain*. 2021;144(4):1263-1276.
438 doi:10.1093/brain/awab009
- 439 25. Sollini M, Morbelli S, Ciccarelli M, et al. Long COVID hallmarks on [18F]FDG-PET/CT:
440 a case-control study. *Eur J Nucl Med Mol Imaging*. 2021;48(10):3187-3197.
441 doi:10.1007/s00259-021-05294-3
- 442 26. Guedj E, Champion JY, Dudouet P, et al. 18F-FDG brain PET hypometabolism in patients
443 with long COVID. *Eur J Nucl Med Mol Imaging*. 2021;48(9):2823-2833.
444 doi:10.1007/s00259-021-05215-4
- 445 27. Kas A, Soret M, Pyatigorskaya N, et al. The cerebral network of COVID-19-related
446 encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. *Eur J Nucl Med Mol*
447 *Imaging*. Published online 2021. doi:10.1007/s00259-020-05178-y
- 448 28. Niesen M, Trotta N, Noel A, et al. Structural and metabolic brain abnormalities in
449 COVID-19 patients with sudden loss of smell. *Eur J Nucl Med Mol Imaging*.
450 2021;48(6):1890-1901. doi:10.1007/s00259-020-05154-6
- 451 29. Whitmore HAB, Kim LA. Understanding the Role of Blood Vessels in the Neurological
452 Manifestations of COVID-19. *Am J Pathol*. Published online June 2021.
453 doi:10.1016/j.ajpath.2021.04.017
- 454 30. Sashindranath M, Nandurkar HH. Endothelial dysfunction in the brain: Setting the stage
455 for stroke and other cerebrovascular complications of covid-19. *Stroke*. 2021;52(5).
456 doi:10.1161/STROKEAHA.120.032711
- 457 31. MacIntosh BJ, Ji X, Chen JJ, et al. Brain structure and function in people recovering from
458 COVID-19 after hospital discharge or self-isolation: a longitudinal observational study
459 protocol. *C open*. 2021;9(4):E1114-E1119. doi:10.9778/cmajo.20210023

- 460 32. Yelin D, Margalit I, Nehme M, et al. Patterns of Long COVID Symptoms: A Multi-Center
461 Cross Sectional Study. *J Clin Med*. 2022;11(4). doi:10.3390/jcm11040898
- 462 33. Sudre CH, Lee KA, Lochlainn MN, et al. Symptom clusters in COVID-19: A potential
463 clinical prediction tool from the COVID symptom study app. *Sci Adv*. 2021;7(12):4177.
464 doi:10.1126/sciadv.abd4177
- 465 34. Hafiz R, Gandhi TK, Mishra S, et al. Assessing functional connectivity differences and
466 work-related fatigue in surviving COVID-negative patients. *bioRxiv Prepr Serv Biol*.
467 Published online February 1, 2022. doi:10.1101/2022.02.01.478677
- 468 35. Hafiz R, Gandhi TK, Mishra S, et al. Higher Limbic and Basal Ganglia volumes in
469 surviving COVID-negative patients and the relations to fatigue. *medRxiv*. Published online
470 November 24, 2021. doi:10.1101/2021.11.23.21266761
- 471 36. Gershon RC, Wagster M V., Hendrie HC, Fox NA, Cook KF, Nowinski CJ. NIH toolbox
472 for assessment of neurological and behavioral function. *Neurology*. 2013;80(11 Suppl
473 3):S2. doi:10.1212/wnl.0b013e3182872e5f
- 474 37. Hodes RJ, Insel TR, Landis SC, NIH Blueprint for Neuroscience Research. The NIH
475 toolbox: setting a standard for biomedical research. *Neurology*. 2013;80(11 Suppl 3):S1.
476 doi:10.1212/wnl.0b013e3182872e90
- 477 38. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania smell
478 identification test: A standardized microencapsulated test of olfactory function. *Physiol*
479 *Behav*. 1984;32(3):489-502. doi:10.1016/0031-9384(84)90269-5
- 480 39. Weintraub S, Dikmen SS, Heaton RK, et al. Cognition assessment using the NIH Toolbox.
481 *Neurology*. 2013;80(11 Suppl 3). doi:10.1212/wnl.0b013e3182872ded
- 482 40. Salsman JM, Butt Z, Pilkonis PA, et al. Emotion assessment using the NIH Toolbox.


- 483 *Neurology*. 2013;80(11 Suppl 3). doi:10.1212/wnl.0b013e3182872e11
- 484 41. Doty RL, Frye RE, Agrawal U. Internal consistency reliability of the fractionated and
485 whole University of Pennsylvania Smell Identification Test. *Percept Psychophys*.
486 1989;45(5):381-384. doi:10.3758/BF03210709
- 487 42. Kilroy E, Apostolova L, Liu C, Yan L, Ringman J, Wang DJJ. Reliability of two-
488 dimensional and three-dimensional pseudo-continuous arterial spin labeling perfusion
489 MRI in elderly populations: Comparison with 15o-water positron emission tomography. *J*
490 *Magn Reson Imaging*. 2014;39(4):931-939. doi:10.1002/jmri.24246
- 491 43. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. *Neuroimage*.
492 2012;62(2):782-790. doi:10.1016/J.NEUROIMAGE.2011.09.015
- 493 44. Groves AR, Chappell MA, Woolrich MW. Combined spatial and non-spatial prior for
494 inference on MRI time-series. *Neuroimage*. 2009;45(3):795-809.
495 doi:10.1016/j.neuroimage.2008.12.027
- 496 45. Chappell MA, McConnell FAK, Golay X, et al. Partial volume correction in arterial spin
497 labeling perfusion MRI: A method to disentangle anatomy from physiology or an analysis
498 step too far? *Neuroimage*. 2021;238. doi:10.1016/j.neuroimage.2021.118236
- 499 46. Chappell MA, Groves AR, Whitcher B, Woolrich MW. Variational Bayesian inference for
500 a nonlinear forward model. *IEEE Trans Signal Process*. Published online 2009.
501 doi:10.1109/TSP.2008.2005752
- 502 47. Yoshiura T, Hiwatashi A, Noguchi T, et al. Arterial spin labelling at 3-T MR imaging for
503 detection of individuals with Alzheimer's disease. *Eur Radiol*. 2009;19(12):2819-2825.
504 doi:10.1007/s00330-009-1511-6
- 505 48. Chappell MA, Groves AR, MacIntosh BJ, Donahue MJ, Jezzard P, Woolrich MW. Partial

- 506 volume correction of multiple inversion time arterial spin labeling MRI data. *Magn Reson*
507 *Med.* 2011;65(4):1173-1183. doi:10.1002/mrm.22641
- 508 49. Winkler EA, Bell RD, Zlokovic B V. Central nervous system pericytes in health and
509 disease. *Nat Neurosci.* 2011;14(11):1398-1405. doi:10.1038/nn.2946
- 510 50. Chen R, Wang K, Yu J, et al. The Spatial and Cell-Type Distribution of SARS-CoV-2
511 Receptor ACE2 in the Human and Mouse Brains. *Front Neurol.* 2021;11.
512 doi:10.3389/fneur.2020.573095
- 513 51. Kirouac GJ. The Paraventricular Nucleus of the Thalamus as an Integrating and Relay
514 Node in the Brain Anxiety Network. *Front Behav Neurosci.* 2021;15.
515 doi:10.3389/fnbeh.2021.627633
- 516 52. Guedj E, Million M, Dudouet P, et al. 18F-FDG brain PET hypometabolism in post-
517 SARS-CoV-2 infection: substrate for persistent/delayed disorders? *Eur J Nucl Med Mol*
518 *Imaging.* 2021;48(2):592-595. doi:10.1007/s00259-020-04973-x
- 519 53. Meyer PT, Hellwig S, Blazhenets G, Hosp JA. Molecular imaging findings on acute and
520 long-term effects of COVID-19 on the brain: A systematic review. *J Nucl Med.* Published
521 online February 17, 2022;jnumed.121.263085. doi:10.2967/jnumed.121.263085
- 522 54. Ismail II, Gad KA. Absent Blood Oxygen Level-Dependent Functional Magnetic
523 Resonance Imaging Activation of the Orbitofrontal Cortex in a Patient with Persistent
524 Cacosmia and Cacogeusia after COVID-19 Infection. *JAMA Neurol.* 2021;78(5):609-610.
525 doi:10.1001/jamaneurol.2021.0009
- 526 55. Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. 18FDG
527 PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. *Acad*
528 *Radiol.* 2020;27(7):1042-1043. doi:10.1016/j.acra.2020.04.030


- 529 56. Hua J, Liu P, Kim T, et al. MRI techniques to measure arterial and venous cerebral blood
530 volume. *Neuroimage*. 2019;187:17-31. doi:10.1016/j.neuroimage.2018.02.027
- 531 57. Draganski B, Kherif F, Klöppel S, et al. Evidence for segregated and integrative
532 connectivity patterns in the human basal ganglia. *J Neurosci*. 2008;28(28):7143-7152.
533 doi:10.1523/JNEUROSCI.1486-08.2008
- 534 58. Fettes P, Schulze L, Downar J. Cortico-striatal-thalamic loop circuits of the orbitofrontal
535 cortex: Promising therapeutic targets in psychiatric illness. *Front Syst Neurosci*. 2017;11.
536 doi:10.3389/fnsys.2017.00025
- 537 59. Maia T V., Frank MJ. From reinforcement learning models to psychiatric and neurological
538 disorders. In: *Nature Neuroscience*. Vol 14. NIH Public Access; 2011:154-162.
539 doi:10.1038/nm.2723
- 540 60. Gottfried JA, Zald DH. On the scent of human olfactory orbitofrontal cortex: Meta-
541 analysis and comparison to non-human primates. *Brain Res Rev*. 2005;50(2):287-304.
542 doi:10.1016/j.brainresrev.2005.08.004
- 543 61. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the
544 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet*.
545 2022;399(10323):437-446. doi:10.1016/S0140-6736(22)00017-4
- 546 62. Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 Omicron virus causes
547 attenuated disease in mice and hamsters. *Nature*. 2022;603(7902). doi:10.1038/s41586-
548 022-04441-6
- 549 63. Bornstein SR, Voit-Bak K, Donate T, et al. Chronic post-COVID-19 syndrome and
550 chronic fatigue syndrome: Is there a role for extracorporeal apheresis? *Mol Psychiatry*.
551 2022;27(1):34-37. doi:10.1038/s41380-021-01148-4

- 552 64. Shungu DC, Weiduschat N, Murrough JW, et al. Increased ventricular lactate in chronic
553 fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms
554 implicate oxidative stress in disorder pathophysiology. *NMR Biomed.* 2012;25(9):1073-
555 1087. doi:10.1002/nbm.2772
- 556 65. Biswal B, Kunwar P, Natelson BH. Cerebral blood flow is reduced in chronic fatigue
557 syndrome as assessed by arterial spin labeling. *J Neurol Sci.* 2011;301(1-2):9-11.
558 doi:10.1016/j.jns.2010.11.018
559

560 6. Figure legends




561
562 **Figure 1.** a) Timing of PCR test (left marker) and assessment (right marker) for COVID-19
563 (orange squares) participants and controls (green circle). Confirmed cases in Ontario are shown
564 in grey. b) Number of days between PCR test and assessment. The black dotted line indicates 28
565 days, an established threshold beyond which symptoms can be considered part of the post-
566 COVID-19 condition. c) Proportion of participants who self-reported flu-like symptoms. Faint
567 bars indicate participants whose symptoms had resolved by the time of the assessment while dark
568 bars indicate participants with on-going symptoms. d) Representative and group-averaged CBF
569 maps from both groups.




570

571 **Figure 2.** Cluster exhibiting significantly decreased CBF in the COVID-19 group (n = 39)
572 relative to controls (n = 11), after controlling for age and sex. No clusters were found where the
573 COVID-19 group had higher CBF compared to controls. Statistical maps are presented in
574 radiological convention. Montreal Neurological Institute coordinates are denoted by z-values.
575 Abbreviations: R, right; L, left.



576

577 **Figure 3.** Cluster exhibiting significantly decreased partial volume-corrected CBF in the
578 COVID-19 group (n = 39) relative to controls (n = 11), after adjusting for age and sex. No
579 clusters were found where the COVID-19 group had higher CBF compared to controls.
580 Statistical maps are presented in radiological convention. Montreal Neurological Institute
581 coordinates are denoted by z-values. Abbreviations: R, right; L, left.



582
583 **Figure 4.** Clusters exhibiting significantly increased (red-yellow) and decreased (blue-green)
584 CBF in the COVID-19 with fatigue group (n = 11) relative to the COVID-19 without fatigue
585 group (n = 28), after controlling for age and sex. Statistical maps are presented in radiological
586 convention. Montreal Neurological Institute coordinates are denoted by z-values. Abbreviations:
587 R, right; L, left.

588 7. Tables

	Controls (n = 11)	COVID-19 (n = 39)	Test Statistic	P
Age (years)	41.5 ± 13.4 [26, 70]	41.9 ± 12.6 [19, 63]	t = 0.10	0.92
Female	6 (54.5%)	27 (69.2%)	X ² = 0.82	0.36
Caucasian	7 (63.6%)	29 (74.4%)	X ² = 0.49	0.48
Education (years)	17.0 ± 2.8 [12, 22]	16.0 ± 2.0 [12, 20]	U = 253.0	0.35
Days between PCR test and time of assessment	112.1 ± 59.5 [25, 206]	116.5 ± 62.2 [8, 312]	t = 0.21	0.84
Received first dose of vaccine prior to time of assessment (yes / no / did not answer)	0 / 3 (27.3%) / 8 (72.7%)	2 (5.1%) / 23 (59.0%) / 14 (35.9%)	X ² = 4.87	0.12
Days between receiving first dose of vaccine and time of assessment	–	[5, 6]	–	–
Self-reported symptoms at time of assessment (current / resolved / did not experience)				
Fatigue	4 (36.4%) / 4 (36.4%) / 3 (27.3%)	11 (28.2%) / 25 (64.1%) / 3 (7.7%)	X ² = 4.07	0.11
Shortness of Breath	3 (27.3%) / 2 (18.2%) / 6 (54.5%)	8 (20.5%) / 12 (30.8%) / 19 (48.7%)	X ² = 0.72	0.74
Smell/Taste Changes	0 / 3 (27.3%) / 8 (72.7%)	7 (17.9%) / 19 (48.7%) / 13 (33.3%)	X ² = 6.04	0.05 *
Cough	1 (9.0%) / 5 (45.5%) / 5 (45.5%)	5 (12.8%) / 24 (61.5%) / 10 (25.6%)	X ² = 1.61	0.49
Gastrointestinal Symptoms	2 (18.2%) / 4 (36.4%) / 5 (45.5%)	5 (12.8%) / 16 (41.0%) / 18 (46.2%)	X ² = 0.22	0.90
Sore Throat	0 / 6 (54.5%) / 5 (45.5%)	1 (2.6%) / 27 (69.2%) / 11 (28.2%)	X ² = 1.36	0.58
Fever	0 / 8 (72.7%) / 3 (27.3%)	0 / 27 (69.2%) / 12 (30.8%)	X ² = 0.05	–
NIH Toolbox Cognition Battery (age-corrected standard scores)				
Fluid Cognition	102.8 ± 15.2 [77, 120]	104.1 ± 16.5 [72, 142]	t = 0.22	0.82
Crystallized Cognition	107.5 ± 12.9 [83, 124]	100.2 ± 12.7 [67, 127]	t = 1.69	0.10
NIH Toolbox Emotion Battery (T-scores)				
Negative Affect	53.5 ± 10.9 [38, 71]	59.0 ± 8.5 [45, 78] {3}	t = 1.78	0.08
Social Satisfaction	44.2 ± 10.4 [23, 61]	46.6 ± 9.5 [27, 66] {3}	t = 0.71	0.48
Well-Being	45.9 ± 8.1 [35, 55]	44.7 ± 6.4 [32, 54] {3}	U = 229.0	0.44
UPSIT				
UPSIT Score	32.7 ± 5.3 [21, 38] {2}	33.4 ± 5.4 [17, 40] {11}	U = 95.0	0.28

Normosmia	5 (55.6%)	13 (46.4%)	$X^2 = 1.85$	0.64
Mild Microsmia	2 (22.2%)	11 (39.3%)		
Moderate Microsmia	1 (11.1%)	1 (3.6%)		
Severe Microsmia	1 (11.1%)	2 (7.1%)		
Total Anosmia	0	1 (3.6%)		

589

590 **Table 1. Demographic and clinical characteristics.** Data are presented as mean \pm standard
591 deviation [minimum, maximum], or count (%). Between-group comparisons were performed
592 using independent samples t-tests or Mann-Whitney U-tests for continuous data and chi-squared
593 tests or Fisher's exact tests for categorical data. Significant differences at $p < 0.05$ are indicated
594 by an asterisk. Numbers in braces indicate participants with missing/faulty data. Abbreviations:
595 PCR, polymerase chain reaction; NIH, National Institutes of Health; UPSIT, University of
596 Pennsylvania Smell Identification Test.

Comparison	Direction	Size	t-statistic	x	y	z	Description
COVID-19 (n = 39) vs. Controls (n = 11)	COVID-19 < Controls	4,431	5.94	4	14	2	Thalamus, Orbitofrontal Cortex, Caudate, Nucleus Accumbens, Putamen, Pallidum
<i>Sensitivity Analysis – Partial Volume Correction</i>							
COVID-19 (n = 39) vs. Controls (n = 11) with partial volume correction	COVID-19 < Controls	2,251	4.83	-4	8	6	Thalamus, Orbitofrontal Cortex, Caudate, Nucleus Accumbens, Putamen, Pallidum
<i>Exploratory Analysis – Effects of Fatigue on CBF within the COVID-19 group</i>							
COVID-19 with fatigue (n = 11) vs. COVID-19 without fatigue (n = 28)	COVID-19 with fatigue > COVID-19 without fatigue	464	4.40	32	-60	50	Superior Lateral Occipital Cortex, Angular Gyrus, Superior Parietal Lobule, Supramarginal Gyrus
	COVID-19 with fatigue < COVID-19 without fatigue	758	4.75	10	-66	-4	Lingual Gyrus, Occipital Fusiform Gyrus, Intracalcarine Cortex, Precuneous Cortex

597

598 **Table 2. Summary of voxel-wise analyses of CBF.** The primary (top row) and secondary
599 analyses (bottom rows) show results of the two-tailed independent samples t-tests that were used
600 to test for between-(sub)group differences, controlling for age and sex. Coordinates indicate
601 location of peak t-statistic.